Runben Biotechnology (603193)2025-01-22 08:15Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 300 million and 310 million yuan, an increase of 73.97 million to 83.97 million yuan compared to the previous year, representing a year-on-year growth of 32.73% to 37.15%[3]. - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 is projected to be between 288.77 million and 298.77 million yuan, an increase of 70.12 million to 80.12 million yuan year-on-year, reflecting a growth of 32.07% to 36.65%[5][6]. - The net profit for the year 2023 attributable to shareholders of the parent company was 226.03 million yuan, with a net profit of 218.65 million yuan after deducting non-recurring gains and losses[8]. - The company achieved an earnings per share of 0.64 yuan for the year 2023[9]. Operational Improvements - The increase in performance is primarily due to the growth in operating revenue, improved operational efficiency, brand awareness, and scale effects[10]. - The company has actively expanded both online and offline channels and increased R&D investment to enhance its product matrix in baby care and mosquito repellent categories[10]. - The company has strengthened operational management, leading to a decrease in management expense ratio year-on-year[10]. Audit and Reporting - The performance forecast has not yet been audited by a registered accounting firm, and the company has communicated with the auditing firm regarding the performance forecast[11]. - Investors are advised to note that the forecast data is preliminary and the accurate financial data will be disclosed in the audited annual report for 2024[12].